Newlin Page 105 Old PolyOne Transformation 60% 80% 100% % o f O p ra ti g I co m * Mix Shift Highlights Specialty Transformation Ahead of Schedule 2015 Target *Operating Income excludes Corporate Charges ** Pro Forma for the acquisition of ColorMatrix and divestiture of SunBelt 2% 34% 42% 50% 65-75% 0% 20% 40% 2005 2008 2011 2011** 2015 % o f O p ra ti g I co m * JV's PP&S Distribution Specialty Specialty OI $5M $46M $89M $117M Target Page 106 Why Invest In PolyOne? Past performance demonstrates that our strategy and execution are working • Megatrends align with our strengths • Innovation and services provide differentiation • Innovation and services provide differentiation and competitive advantage • Strong and proven management team driving growth and performance The New PolyOne: A Specialty Growth Company 2015 Target: $2.50 Adjusted EPS Page 107 Thank You Questions & Answers Page 108

Common Types & Deniers Multi-filament and Spun Various deniers available

™ Fillers & Reinforcements We take an objective look at the types of polymer fillers and reinforcements available and which ones will give you the results you’re seeking.

Single product solution - can be used with any type of PET base resin

Among all the different types of plastics on the market today, why would anyone choose polyaryletherketones (PAEK), polysulfones (PSU), liquid crystal polymers (LCP), polyetherimides (PEI) and polyphenylene sulfides (PPS) for their application?

SPECIALTY INKS OVERVIEW PolyOne Specialty Inks is a leading global manufacturer of screen printing inks for the textile industry and of specialty inks for industrial applications. PolyOne makes no warranties or guarantees respecting suitability of either PolyOne’s products or the information for your process or end-use application. POLYONE MAKES NO WARRANTIES, EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE, either with respect to the information or products reflected by the information.

Color and additive masterbatches formulated with bio-based polymers to increase sustainability

Color and special effect masterbatches pre-tested to ISO, US Pharmacopeia, European Pharmacopoeia, and ICH Q3D protocols for differentiation and patient adherence support

Custom masterbatches for coloration and enhanced properties

Factors that could cause actual results to differ materially from those implied by these forward-looking statements include our ability to identify and evaluate acquisition targets and consummate acquisitions; the ability to successfully integrate acquired businesses into our operations, such as Magna Colours, retain the management teams of acquired businesses, and retain relationships with customers of acquired businesses; our ability to achieve the strategic and other objectives relating to the acquisition of Clariant's Masterbatch business, including any expected synergies; disruptions, uncertainty or volatility in the credit markets that could adversely impact the availability of credit already arranged and the availability and cost of credit in the future; the effect on foreign operations of currency fluctuations, tariffs and other political, economic and regulatory risks; the current and potential future impact of the COVID-19 pandemic on our business, results of operations, financial position or cash flows; changes in polymer consumption growth rates and laws and regulations regarding plastics in jurisdictions where we conduct business; fluctuations in raw material prices, quality and supply, and in energy prices and supply; production outages or material costs associated with scheduled or unscheduled maintenance programs; unanticipated developments that could occur with respect to contingencies such as litigation and environmental matters; an inability to achieve the anticipated financial benefit from initiatives related to acquisition and integration working capital reductions, cost reductions and employee productivity goals; information systems failures and cyberattacks; and amounts for cash and non-cash charges related to restructuring plans that may differ from original estimates, including because of timing changes associated with the underlying actions.